Latest news for Carl Zeiss Meditec (OTC:CZMWY) Stock

CARL ZEISS MEDITEC

Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Analyst Color

Long Ideas

News

Short Ideas

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

CZMWY

Innovation and digitalization have been in focus among ophthalmology majors.

Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: &#39;Innovation Is Key&#39;

Emerging Markets

Small Cap

Markets

TOPCF

Vision is the most cherished of the five senses. Losing your eyesight can have a tremendously debilitating impact on your day-to-day life.

24% of American Dont Have Vision Care: Here&#39;s Why

Tech

Image provided by Retina Technologies

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Technology That Could Catch Vision Problems Early And Save Your Eyesight?

CARL ZEISS MEDI UNSP/ADR by Carl Zeiss Meditec AG

Carl Zeiss Meditec AG

Carl Zeiss Meditec: One Of The Highest Premiums I'll Accept

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>With markets remaining choppy and sentiment still cautious, many quality stocks are trading at tempting valuations. Recent indiscriminate selling has knocked down the valuations of profitable, growing companies to levels that don&rsquo;t accurately reflect their long-term potential. Savvy investors can exploit this disconnect by identifying and buying shares in temporarily-mispriced businesses.</p>
<p>Though broader macroeconomic challenges persist, these companies operate successful business models that should drive significant shareholder value creation over the long term. Some industry leaders have simply been oversold due to this risk-off environment. Others face short-term headwinds, but have levers to pull to reaccelerate their growth. And some are great businesses unfairly tarnished by association with struggling sectors.</p>
<p>Of course, further market declines may pressure stocks lower still in the near term. But buying companies with strong fundamentals at these levels enables outsized returns once the tide eventually turns. Here are the seven most <a href="https://investorplace.com/stock-types/undervalued-stocks/">undervalued stocks</a> to look into:
</p>
<h2>Carl Zeiss Meditec (CZMWF)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2020/07/surgery-rtix-1600-300x169.jpg" alt="surgeons operating on a patient" width="300" height="169"><div>Source: Dmytro Zinkevych / Shutterstock.com</div></div>
<p><strong>Carl Zeiss Meditec</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/czmwf-stock-quote/"><strong>CZMWF</strong></a>) is down almost 40% from its 52-week highs despite reporting robust Q3 results. The microsurgery company&rsquo;s revenue <a href="https://www.zeiss.com/content/dam/meditec-ag/financial-communication/9m2223/afx_quarterly_statement_9m2223.pdf">grew 12.9%</a> year-over-year on a currency-adjusted basis to &euro;1.51 billion. This broad-based growth was driven by its Ophthalmic Devices and Microsurgery segments.</p>
<p>Carl Zeiss continues to benefit from powerful demographic trends, including an aging global populations and the rising prevalence of eye diseases. The company estimates the cataract surgery market will sustain mid-single digit growth, while premium intraocular lenses represent a massive opportunity growing at 10%+ annually. With its advanced technology in lasers, intraocular lenses and visualization systems, Carl Zeiss is well positioned to capitalize on these strong tailwinds.</p>
<p>Even with the healthy revenue growth, and temporary factors like China lockdowns, supply chain issues fading away and rebounding margins this quarter, the stock is yet to rebound. At current valuations around 24-times forward earnings, the stock seems to price in an excessively negative scenario, in my opinion. As macro conditions eventually stabilize, Carl Zeiss&rsquo; long-term growth story should regain momentum. Analysts <a href="https://seekingalpha.com/symbol/CZMWY/earnings/estimates">expect</a> the top-line growth here to hover near double digits for the foreseeable future. Accordingly, the average analyst expects <a href="https://www.tipranks.com/stocks/gb:0dhc/forecast">40% upside</a> in one year.</p>
<h2>JinkoSolar (JKS)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2020/06/jks-stock-300x169.jpg" alt="The JinkoSolar logo displayed on a plain white wall." width="300" height="169"><div>Source: Lutsenko_Oleksandr / Shutterstock.com</div></div>
<p>As one of the largest solar module suppliers globally, <strong>JinkoSolar</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/jks-stock-quote/"><strong>JKS</strong></a>) operates an integrated production network spanning silicon wafers to solar modules. However, negative market sentiment due to Chinese regulatory risks has driven JKS stock down over 60% from 2022 highs, now trading at just 3-times forward earnings. This seems like a huge overreaction, creating a compelling bargain buy for long-term investors.</p>
<p>First things first, the company&rsquo;s revenue growth is <a href="https://seekingalpha.com/article/4628212-jinkosolar-holding-co-ltd-jks-q2-2023-earnings-call-transcript">above 50%,</a> as of the latest quarter. JinkoSolar beat analyst estimates for revenue by a massive $210 million, and beat on its earnings per share number ($5.78 compared to estimates of $3.52)! JKS has demonstrated outstanding execution, even amidst challenging conditions. The company also reported 65.6% sequential growth in net income, driven by a 36% jump in solar module shipments. Its next-gen N-type modules already comprise 58% of shipments, underscoring its technology leadership. JKS expects N-type to reach 60-65% of shipments in the coming quarters.</p>
<p>With fully integrated operations spanning silicon ingots to solar modules, JKS enjoys significant cost advantages relative to non-integrated peers. Its global manufacturing footprint extends throughout China, Southeast Asia, and the U.S. This footprint allows JinkoSolar the flexibility to navigate regulatory risks and tariffs. Currently, the company sees no impact from the recent U.S. ban on Chinese solar imports.</p>
<p>Looking ahead, JinkoSolar issued upbeat guidance expecting full-year module shipments of 70-75 GW, implying over 25% growth. Its mass production capabilities for next-gen high-efficiency N-type modules should support continued market share gains. Trading at just 0.09-times sales and 3-times forward earnings, JKS stock is undoubtedly among the most undervalued <a href="https://investorplace.com/industries/energy/renewable-energy/solar/">solar stocks</a> now. This creates a very compelling risk-reward proposition for investors who can look past short-term volatility.</p>
<h2>Advance Auto Parts (AAP)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2022/11/aap1600-300x169.jpg" alt="The outside of an Advanced Auto Parts storefront." width="300" height="169"><div>Source: James R. Martin / Shutterstock</div></div>
<p><strong>Advance Auto Parts</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/aap-stock-quote/"><strong>AAP</strong></a>) operates a network of over <a href="https://ir.advanceautoparts.com/investors/news-and-events/press-releases/press-release-details/2023/Advance-Auto-Parts-Reports-Second-Quarter-2023-Results/default.aspx">4,790 auto parts stores</a>, catering to both retail do-it-yourself customers and professional installers. The company has faced margin headwinds this year from elevated inflation and investments to improve parts availability. This led to a 66%+ decline in AAP stock price from 52-week highs. However, I believe the market has overreacted, and AAP stock looks like among the most undervalued options among its peers right now.</p>
<p>In <a href="https://seekingalpha.com/article/4630599-advance-auto-parts-inc-aap-q2-2023-earnings-call-transcript">Q2 results</a>, Advanced Auto Parts delivered positive net sales growth despite comparable store sales dipping 0.6%. Importantly, sales trends improved sequentially, with comparable store sales slightly increasing over the last four weeks. The company is seeing traction from initiatives to boost parts availability and maintain competitive pricing. Supply chain investments are also helping improve inventory close rates.</p>
<p>Looking ahead, powerful secular tailwinds should drive accelerating demand for auto parts. The average age of vehicles on U.S. roads is at a record high today. Plus, high inflation means fewer consumers can afford new car purchases, necessitating higher spending on maintenance and repairs.</p>
<p>Meanwhile, Advanced Auto Parts is continuing its pivot towards higher-margin-owned brands, which should support gross margin improvement over time. The company does face near-term headwinds from elevated costs and its pricing strategy. However, Advanced Auto Parts has targeted significant improvements through supply chain optimization, cost savings, and asset productivity. While growth in 2023 will likely be muted, the long-term growth story remains intact. The current undervaluation with AAP stock provides an attractive entry point for investors.</p>
<h2>Farmers and Merchants Bank of Long Beach (FMBL)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2023/04/safe-bank-vault-light-1600-300x169.jpg" alt="Golden light shining from crack of door on black safe with black background, representing bank stocks" width="300" height="169"><div>Source: shutterstock.com/marozhka studio</div></div>
<p><strong>Farmers and Merchants Bank of Long Beach</strong> (OTCMKTS:<span><strong>FMBL</strong></span>) is a community bank operating in California since 1907. The outlook for regional banks has weakened considerably amidst economic uncertainty, sending FMBL stock down close to 36% from 52-week highs. However, this excessive pessimism has created a buying opportunity in this high-quality regional bank.</p>
<p>Despite the tough operating environment, I expect a strong recovery over the long-run. For now, the rising rate environment will impact near-term profitability. And unfortunately, there is little to analyze with this stock, due to its size.</p>
<p>However, as per <em>Gurufocus&rsquo;</em> model, they <a href="https://www.gurufocus.com/stock/FMBL/summary">believe</a> FMBL&rsquo;s fair price will be at $8,000 by the end of this year and believe the stock is significantly undervalued.</p>
<p>Regardless, FMBL maintains a rock-solid balance sheet, ending the quarter with capital ratios substantially above regulatory requirements. Its credit quality also remains resilient, with <a href="https://ir.fm.bank/news-releases/news-release-details/farmers-merchants-bancorp-inc-reports-2023-second-quarter-and">non-performing loans below 0.25% of total loans</a>. While many regional banks are struggling, FMBL seems well-positioned to weather near-term headwinds.</p>
<p>Trading at just 0.48-times on a price-to-tangible-book value basis, and 7-times forward earnings, FMBL stock is undoubtedly cheap for a profitable bank of its caliber. The stock also offers an attractive dividend yield of 2.2%. While risks exist in this uncertain environment, the risk-reward now seems skewed positively for long-term investors, adding exposure at current levels.</p>
<h2>Insulet Corporation (PODD)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2022/04/medical-device-stocks-hospital-stocks-healthcare-stocks-300x169.jpg" alt="An image of two medical professionals performing a procedure on a patient" width="300" height="169"><div>Source: Roman Zaiets / Shutterstock.com</div></div>
<p>Shares of <strong>Insulet Corporation</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/podd-stock-quote/"><strong>PODD</strong></a>) have plunged by nearly 47% since May despite the medical device company beating estimates and delivering <a href="https://seekingalpha.com/article/4625764-insulet-corporation-podd-q2-2023-earnings-call-transcript?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A7">stellar top and bottom line growth</a> in its most recent quarter. Insulet is the maker of the Omnipod system for diabetes management. The stock&rsquo;s steep decline reflects worries that new diabetes drugs like <strong>Eli Lilly&rsquo;s</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/"><strong>LLY</strong></a>) Mounjaro could have a major negative impact on Insulet&rsquo;s insulin pump business.</p>
<p>However, I believe these competitive concerns are overexaggerated. Insulet just reported record revenue in Q2, up 32.4% year-over-year. Its flagship Omnipod 5 product saw U.S. sales surge 41%. The company is also expanding Omnipod 5&rsquo;s rollout internationally. Though new medication options may modestly dampen pump demand, Insulet still has an incredible opportunity to grow over the long-term, as its diabetes tech platform continues taking market share.</p>
<p>Even if we assume the company takes a significant hit from new competition, Insulet&rsquo;s current valuation reflects an overly dire scenario. Shares trade at just 55-times forward earnings with a price-to-sales ratio of 8-times. That suggests the market expects minimal growth, an unlikely outcome given Omnipod 5&rsquo;s early success and the still highly underpenetrated insulin pump market. Insulet also has a pristine balance sheet to lean on during any temporary slowdown.</p>
<h2>Innovative Industrial Properties (IIPR)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2019/08/industrials1600e-300x169.jpg" alt="workers on a construction site with the sun setting in the background" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><strong>Innovative Industrial Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/iipr-stock-quote/"><strong>IIPR</strong></a>) has faced its own struggles over the past two years. Shares are down almost 70% from its peak. The cannabis industry-focused REIT has dealt with tenant struggles, including some missed rental payments. Investors worried about the shaky financial health of IIPR&rsquo;s cannabis tenants have clearly been dumping this stock.</p>
<p>However, the worst seems behind for Innovative Industrial Properties. Collections have improved, after the company negotiated lease amendments with distressed tenants. IIPR is also being more conservative with capital deployment in the current environment. Additionally, its existing properties support an attractive dividend, which was recently <a href="https://seekingalpha.com/article/4623494-innovative-industrial-properties-inc-iipr-q2-2023-earnings-call-transcript">increased by 11%</a> year-over-year.</p>
<p>With tailwinds from broader cannabis legalization still ahead, IIPR&rsquo;s experienced management team is positioned to drive growth for years to come. The REIT collects very high yields on its properties, given cannabis companies&rsquo; limited access to traditional financing. Once capital markets normalize, demand for IIPR&rsquo;s specialized facilities should reignite.</p>
<p>After substantial multiple compression, Innovative Industrial Properties trades at just <a href="https://www.gurufocus.com/term/price_to_ffo/IIPR/Price-to-Funds-From-Operations/IIPR">11-times forward FFO</a>, a massive discount to historical valuations. The stock appears positioned for a gradual turnaround as financial conditions improve industry-wide.</p>
<h2>FMC Corporation (FMC)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2020/02/chemicals-300x169.jpg" alt="Detail of chemical plant, silos and pipes" width="300" height="169"><div>Source: Shutterstock</div></div>
<p><strong>FMC Corporation</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/fmc-stock-quote/"><strong>FMC</strong></a>), a diversified chemical company, has also endured steep valuation multiple contraction in 2023. Shares are down 40% year-to-date and trade near 5-year lows. The stock swoon reflects FMC&rsquo;s <a href="https://investors.fmc.com/news/news-details/2023/FMC-Corporation-announces-second-quarter-results-and-confirms-full-year-outlook/default.aspx#:~:text=Consistent%20with%20the%20company's%20release,to%20%241.40%20billion%2C%20representing%204">expectation for a 9% revenue decline</a> this year, driven by reduced pesticide demand. However, this headwind is temporary.</p>
<p>Wall Street analysts <a href="https://seekingalpha.com/symbol/FMC/earnings/estimates">forecast</a> FMC will deliver 7.7% revenue growth in 2024 as agricultural markets stabilize. Over the long term, FMC should achieve around 5% annual growth thanks to its robust product pipeline and strategic pivot toward higher-value offerings. Margin expansion will also likely accompany revenue growth.</p>
<p>Despite the difficult operating environment, FMC continues generating solid cash flows. Its dividend yield sits at an attractive 3% after <a href="https://www.dividend.com/stocks/materials/chemicals/agricultural-chemicals/fmc-fmc-corp/">5 straight years of payout hikes</a>. At only 12-times forward earnings, FMC stock reflects undue pessimism about its future prospects. The company has successfully navigated prior industry downturns. Once macro conditions improve, FMC&rsquo;s discounted valuation sets up a substantial upside. The consensus price target is at $110, implying over <a href="https://www.tipranks.com/stocks/fmc/forecast">47% upside</a> in one year&rsquo;s time.</p>
<p><em>On the date of publication, Omor Ibne Ehsan did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral" target="_blank">Publishing Guidelines</a>.</em></p>
<div>
<p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p>
</div>
<h3>More From InvestorPlace</h3>
<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT758392">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT758390">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT758396">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
</ul><div>
<div>
<div></div>
<div></div>
</div>
</div>

<p>The post <a href="https://investorplace.com/2023/09/the-7-most-undervalued-stocks-in-the-market-right-now-september-2023/">The 7 Most Undervalued Stocks in the Market Right Now: September 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 7 Most Undervalued Stocks in the Market Right Now: September 2023

Carl Zeiss Meditec: Premiums Are Proven To Be Dicey In This Market

Carl Zeiss Meditec to acquire Dutch Ophthalmic for around $1.08B

Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential

Carl Zeiss Meditec AG goes ex dividend tomorrow

Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript

Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside

CZMWF

FMBL

IIPR

PODD

Press Releases

Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market

ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care

Carl Zeiss Meditec

<p>Innovation and digitalization have been in <a href="https://www.benzinga.com/general/biotech/23/01/30352967/novartis-ceo-refutes-recent-report-of-weighing-options-for-ophthalmology-respiratory-units">focus among ophthalmology majors</a>.</p>

<p>The ophthalmology market is attractive, at an estimated $34 billion, with growth rates &ldquo;in the mid-single digits across products that range from the clinic to the operating room to the pharmacy,&rdquo; analyst Susannah Ludwig of Bernstein said in a note.</p>

<ul>
	<li>Initiated coverage of <strong>Alcon AG</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with an Outperform rating and a price target of CHF 82 ($94.03).</li>
	<li>Initiated coverage of <strong>Carl Zeiss Meditec AG</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CZMWY#OTC">CZMWY</a>) with an Underperform rating and a price target of &euro;76 ($82.31).</li>
</ul>

<p><em>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.</em></p>

<p><strong>The Ophthalmology Thesis</strong>: &ldquo;With high unmet need and low penetration, innovation is key to success in the market. Innovative products not only drive higher penetration,&rdquo; Ludwig wrote.</p>

<p>Alcon, the largest player in surgical, outspends the next player by 1.9x in R&amp;D, while Zeiss is much smaller in scale and &ldquo;spends a mid-teens % of sales on R&amp;D, a level they will likely have to keep up as competition has refocused on innovation and as digital becomes more important,&rdquo; she added.</p>

<p>&ldquo;Surgical ophthalmology remains incredibly manual,&rdquo; the analyst said. &ldquo;Zeiss leads the digital market today, but we see Alcon as the biggest beneficiary of the industry transition,&rdquo; she further stated.</p>

<p><strong>ALC, CZMWY Price Action: </strong>Shares of Alcon and Carl Zeiss Meditec had declined by 2.34% to CHF 66.82 and by 0.95% to &euro;97.62, respectively, at the time of publication Tuesday.</p>

<p><em>Image: Shutterstock</em></p>

<p>&nbsp;</p>


Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key'

<p>Vision is the <a href="https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2752217#:~:text=Findings%20This%20cross%2Dsectional%20online,valued%20sense%2C%20followed%20by%20hearing.">most cherished of the five senses</a>. Losing your eyesight can have a tremendously debilitating impact on your day-to-day life. Unfortunately, vision impairment is an all-too-common reality plaguing millions of Americans.&nbsp;</p>

<p>In one of the richest countries in the world with some of the most advanced medical equipment, millions reportedly suffer from largely treatable, undiagnosed vision impairments.&nbsp;</p>

<p>Nearly <a href="https://www.cdc.gov/visionhealth/basics/ced/fastfacts.htm">12 million</a> Americans ages 40 and older have some type of vision impairment. But adults aren&rsquo;t the only group affected. Up to 1 in 17 preschool children have an undiagnosed and untreated vision disorder. Another 93 million American adults are at high risk for serious vision loss, but only half visited an eye doctor in the past 12 months.&nbsp;</p>

<p>The surprising figures can be attributed to a variety of causes, with diabetes and poor health being major contributors. However, lack of adequate access to vision care also seems to be a serious problem. In the United States, nearly <a href="https://www.retina-technologies.com/">24%</a> of counties are without an optometrist or ophthalmologist.</p>

<p>Existing technology required to screen a person&rsquo;s vision is often expensive and takes up a lot of space. To properly equip an ophthalmologist or optometrist office, the initial cost can be upwards of $150,000.&nbsp;</p>

<p>The necessary machinery can weigh up to 150 pounds and take up multiple rooms. Paying a certified technician to maintain the equipment is another expense. These requirements can make it difficult to start or maintain a vision practice. Primary care may also struggle to assemble the necessary resources to perform comprehensive vision exams.&nbsp;</p>

<p>All these factors could also be compounded when it comes to lower socio-economic areas. Poor Americans are often at greater risk for visual impairment and a higher prevalence of eye diseases.&nbsp;</p>

<h2>How To Make Vision Care More Accessible?</h2>

<p>In 2018, five medical students set out to make quality vision screening more accessible to traditionally underserved groups using advanced digital technologies. They founded <strong>Retina Technologies Inc.</strong>, whose reported mission centers on bringing comprehensive digital vision screening to virtually any community, especially those critically lacking in eye doctors.&nbsp;</p>

<p>Retina Technologies says its approach is to equip primary care physicians (PCPs) with the technology needed to conduct eye screenings in a fast, cost-effective way. The company states that its system &mdash; OcuVue&trade; &mdash; allows for fast, functional visual exams and retinal imaging within 15 minutes. Proprietary algorithms work to process patient data in seconds, delivering simple referral recommendations to specialists when visual abnormalities are detected.</p>

<p>Retina Technologies&rsquo; OcuVue&trade; might provide an affordable end-to-end vision-screening solution for PCPs, vision-care providers and other specialists, enabling them to more effectively treat and prevent vision impairments. Retina has already emerged as a player in the space - alongside the likes of <strong>Topcon Corp.</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TOPCF#OTC">TOPCF</a>) and <strong>Carl Zeiss Meditec AG</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CZMWY#OTC">CZMWY</a>), and currently has a regulatory CF campaign <a href="https://www.startengine.com/retina-tech?utm_source=article&amp;utm_medium=benzinga&amp;utm_campaign=reg_cf&amp;utm_id=se-promote-retina-tech&amp;utm_term=article4">live on StartEngine</a> for interested investors.</p>

<p>Learn more about Retina Technologies and improvements in vision care accessibility at <a href="https://www.retina-technologies.com/">retina-technologies.com</a>.&nbsp;</p>

<p>Featured photo by<a href="https://unsplash.com/@dtravisphd?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText"> David Travis</a> on<a href="https://unsplash.com/s/photos/blurry-vision?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText"> Unsplash</a></p>

<p><em>This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.</em><br />
&nbsp;</p>

<p><em>The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer&rsquo;s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information.</em></p>


24% of American Dont Have Vision Care: Here's Why

<p><em>Image provided by Retina Technologies</em></p>

<p><em>This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.</em></p>

<p>Eye testing that reduces time, cost and footprint? That is the vision of one startup company that says it is seeking to make eye care more accessible and save patients from preventable blindness by using advanced digital technologies. .</p>

<p>While <a href="https://www.startengine.com/retina-tech/?utm_source=Benzinga&amp;utm_medium=Benzinga&amp;utm_campaign=se-promote-retina-tech-Benzinga2&amp;utm_content=Benzinga-article-2-TTCCVPEASYE"><strong>Retina Technologies</strong></a>&rsquo; (RetTech) OcuVueTM products are in prototype and not yet commercially available, the company believes they can radically change the way eye care is administered and make such care far more available to underserved communities both in the United States and globally.</p>

<p>RetTech reports that the technology involves compact, modular hardware with integrated machine learning enabling fast data interpretation, avoiding the need for bulky and expensive,&nbsp; ophthalmic devices and large amounts of office space. The company has successfully completed clinical trials for its virtual reality module functional vision exams and is developing a highly compact retinal imaging module for high-definition retinal photography. The virtual reality clinical trial was performed in conjunction with New York Eye and Ear Infirmary of Mount Sinai, one of the leading vision-care centers worldwide.</p>

<h2>An Attractive Option For All Healthcare Providers?</h2>

<p>&nbsp;</p>

<p>One of the attractive characteristics of the OcuVueTM Digital Vision Screening Platform is that RetTech is confident it could enable it to gain traction with its relative ease of use. There is no specialist training required to use the technology, making it something that could be offered by primary care providers (PCPs) as part of a routine patient examination as opposed to relying on specialist vision service providers. The tests are also much faster than current in-office technologies, creating a lot of value for PCPs and vision specialists.&nbsp;</p>

<p>When approximately a quarter of U.S. counties reportedly have no access to eye-care providers, this could be a welcome offering in local PCP offices. And best of all, the OcuVueTM platform will be capable of testing for the most important components of vision, including acuity, color deficits, oculomotor function, visual fields, warping, contrast sensitivity, and pupillometry. This drastically increases the probability of catching diseases early.</p>

<p>&ldquo;Our goal is to deliver a great patient and physician user experience with seamless integration into clinical workflows and healthcare systems,&rdquo; the company says.</p>

<p>Retina Technologies was founded in 2018 by five medical students who say they understood how advanced digital technologies could radically improve patient outcomes in communities that have limited or no access to conventional eye care services. They saw the situation firsthand while volunteering in communities where too many patients had previously undiagnosed vision loss.</p>

<p>RetTech reports that data shows that with early detection, up to 80% of the patients could have had their vision saved or vastly improved with the type of accessible, easy-to-use diagnostic techniques the company&rsquo;s digital OcuVue&trade; technology offers.</p>

<p>Major eye-care technology manufacturers globally include Japan-based <strong>Topcon Corp. </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TOPCF#OTC">TOPCF</a>) and Germany&rsquo;s <strong>Carl Zeiss Meditec AG</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CZMWY#OTC">CZMWY</a>).</p>

<p>The global ophthalmology diagnostic tools market is worth approximately $2.7 billion and growing at 5.4% a year. The U.S. eye examination market is worth about $5 billion.</p>

<p><em>This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.</em></p>

<p><em>The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer&rsquo;s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information.</em></p>

<p>&nbsp;</p>


<p><em>Picture credit: Mari Lezhava on </em><a href="https://unsplash.com/photos/q65bNe9fW-w"><em>Unsplash</em></a></p>

<p><em>This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.</em></p>

<p>According to analysts, the global ophthalmology diagnostic tools market is worth approximately $2.7 billion and growing at 5.4% a year &mdash; with the overall United States eye examination market worth about $5 billion.</p>

<p>However, a reported trouble is that, despite this growth, many people have limited or no access to routine eye care, including the 24% of U.S. counties that don&rsquo;t even have eye specialists on the ground. The lack of access may end up resulting in undiagnosed vision loss and contributes to hundreds of thousands of cases of severe vision loss every year in the U.S. alone, 80% of which is avoidable.</p>

<p>Startup <a href="https://www.startengine.com/retina-tech?utm_source=article&amp;utm_medium=benzinga&amp;utm_campaign=reg_cf&amp;utm_id=se-promote-retina-tech&amp;utm_term=article1"><strong>Retina Technologies</strong></a> says it is on a mission to change that.</p>

<p>Co-founded by five medical students in 2018 who had been working in underserved communities and said they saw the lack of access firsthand, Retina Technologies&rsquo; stated concept is to use advanced digital technologies that are easy to use and eliminates the need for advanced specialist training.</p>

<p>That way, the technology might get into the hands of primary care providers (PCPs) who can easily administer the diagnostic technology quickly, and at the fraction of the cost of more conventional tools that require a specialist.</p>

<h2>OcuVue The Way to Go?</h2>

<p>The digital technology is called OcuVue&trade;, a prototype vision testing headset that Retina Technologies reports takes about 15 minutes to administer. If abnormalities are found, a referral recommendation is provided by integrated machine learning algorithms to ensure patients make it to vision specialists who can provide treatment.</p>

<p>Common abnormalities the technology is designed to detect include glaucoma, macular degeneration and diabetic retinopathy.</p>

<p>While hopefully helping patients who would otherwise not have had access to routine healthcare, health providers might also gain using the technology.</p>

<p>&ldquo;For under-resourced PCPs and other frontline healthcare providers everywhere, this means a new revenue stream and more patients referred to vision specialists through early detection, creating better outcomes for everyone,&rdquo; Retina Technologies says. &ldquo;We believe OcuVue will play a vital role in helping people keep their sight.&rdquo;</p>

<p>The<a href="https://www.startengine.com/retina-tech?utm_source=article&amp;utm_medium=benzinga&amp;utm_campaign=reg_cf&amp;utm_id=se-promote-retina-tech&amp;utm_term=article1"> OcuVue&trade; project </a>has the backing of The New York Eye and Ear Infirmary affiliated with Mount Sinai Hospital.</p>

<p>Major eye-care technology manufacturers globally include Japan-based <strong>Topcon Corp. </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TOPCF#OTC">TOPCF</a>) and Germany&rsquo;s <strong>Carl Zeiss Meditec AG</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CZMWY#OTC">CZMWY</a>).</p>

<p><em>This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.</em></p>

<p><em>The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer&rsquo;s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information.</em></p>


Retina Technologies Says It's Looking To Make Eye Care More Accessible, Especially For Those Traditionally Underserved

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Carl Zeiss Meditec

News

Latest news for Carl Zeiss Meditec (OTC:CZMWY) Stock

Tuesday, January 23, 2024

Wednesday, June 15, 2022

Thursday, May 12, 2022

Tuesday, May 03, 2022

Tuesday, July 23, 2019